1. any hospitalization for covid-19 symptoms or complications prior to randomization; 2. use of montelukast ≤ 30 days to screening; 3. any contraindication to montelukast; and 4. any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.

1. any hospitalization for covid-19 symptoms or complications prior to randomization; 2. use of montelukast ≤ 30 days to screening; 3. any contraindication to montelukast; and 4. any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.

any hospitalization for covid-19 symptoms or complications prior to randomization; use of montelukast ≤ 30 days to screening; any contraindication to montelukast; and any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.

any hospitalization for covid-19 symptoms or complications prior to randomization; use of montelukast ≤ 30 days to screening; any contraindication to montelukast; and any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.

1. any hospitalization for covid-19 symptoms or complications prior to randomization; 2. use of montelukast ≤ 30 days to screening; 3. any contraindication to montelukast; and 4. any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.

1. any hospitalization for covid-19 symptoms or complications prior to randomization; 2. use of montelukast ≤ 30 days to screening; 3. any contraindication to montelukast; and 4. any condition (including the inability to swallow pills) which, in the opinion of the principal investigator, would prevent full participation in and compliance with the trial protocol, or would interfere with the evaluation of trial endpoints.